Hepa Thera’s HT-101 Secures Breakthrough Therapy Designation from China CDE for Chronic Hepatitis B

Hepatitis B severely impacts the physical health and quality of life of hundreds of millions of patients worldwide. Functional cure of hepatitis B represents the earnest hope of the vast patient population. Xingyao Kunze has developed a differentiated, innovative combination therapeutic strategy centered on HT-101 and HT-102, which has demonstrated promising functional cure potential in clinical development. As the lead investor in this financing round, Kaitai Capital strongly recognizes the Company's long-term value across its core pipeline, clinical advancement capabilities, and global development pathway. Patients are waiting. We look forward to working alongside all shareholders to support the Company in accelerating pivotal clinical studies and industrialization deployment, enabling the earliest possible market launch of its breakthrough curative therapies to bring hope to hepatitis B patients worldwide.

Functional cure of hepatitis B is the earnest aspiration of patients worldwide. The HT-101 and HT-102 combination regimen developed by Xingyao Kunze has demonstrated breakthrough potential in clinical development. Fosun Pharma has long been deeply committed to the liver disease therapeutic area, and we remain dedicated to delivering superior treatment options for patients. This investment represents not only a significant expansion of Fosun Pharma's pipeline in hepatitis B therapeutics, but also a firm commitment to supporting original innovation from China and empowering domestic innovative drugs to reach global markets. We will fully leverage our strengths in clinical research, industrialization, and global commercialization networks to collaborate with partners across the ecosystem, accelerating the delivery of this breakthrough therapy to patients worldwide at the earliest opportunity.

The core pipeline HT-101/HT-102 of Xingyao Kunze has demonstrated excellent clinical data to date. We are highly optimistic about the product's future approval potential and commercial opportunities. Meanwhile, Fosun Health Capital and the management team of Xingyao Kunze have demonstrated exceptional professional capabilities and execution excellence. As an innovative drug R&D platform incubated and established by Fosun Health Capital, Xingyao Kunze represents a more efficient translational model for innovative drug development under the high synergy of capital and industry. We look forward to working together with all shareholders to continue supporting the Company in accelerating core pipeline development, delivering breakthrough solutions for the global hepatitis B treatment landscape.

In this round, we have chosen to continue increasing our investment in Xingyao Kunze. Its innovative pipeline products have advanced smoothly through clinical trials, with outstanding technical advantages and compelling data, demonstrating tremendous commercialization potential both domestically and internationally. As an early-stage investor, we have personally participated in and witnessed Xingyao Kunze forging an innovative path of synergistic development across capital, intellectual property, R&D, and operations. It is precisely this innovative incubation and development model that has enabled the Company to navigate various challenges with composure over the past few years, with its foundational strength growing increasingly robust. We believe this development model can serve as a reference for numerous domestic biotech enterprises. Going forward, we will remain a committed partner throughout, providing deep companionship as the Company completes its full development cycle.

China represents the largest market for hepatitis B, with clear unmet clinical needs. Small nucleic acid therapeutics bring breakthrough potential for clinical cure of hepatitis B. We are pleased to participate in this financing round of Xingyao Kunze. Qianhe Capital highly recognizes the progress the Company has achieved in the functional cure of hepatitis B, and is optimistic about the development potential of its core pipeline. We very much look forward to the continued smooth advancement of the Company's core products, enabling more hepatitis B patients to benefit at the earliest opportunity.

Xingyao Kunze is an important platform company incubated by Fosun Health Capital New Drug Fund, focused on cutting-edge innovation in major disease areas. The Company has established a clear product strategy and differentiated competitive advantages in the functional cure of chronic hepatitis B. Going forward, Fosun Health Capital will continue to support the Company in leveraging Fosun Pharma's global, industrialization, and clinical development resources to accelerate core pipeline advancement, and in empowering China's original innovative therapies to reach global markets. Meanwhile, we would also like to extend our sincere gratitude to new shareholders, including Kaitai Capital, for their strong recognition of and steadfast support for Xingyao Kunze. We look forward to working hand in hand with all parties to jointly accelerate clinical breakthroughs in the functional cure of hepatitis B.